Argos Therapeutics Inc fka ARGSQ

[declaes]

So when the independent data monitoring committee (DMC) concluded that ARGS lead candidate, rocapuldencel-T, may not be able to achieve the primary endpoints in an ongoing Phase 3 clinical trial.ARGS droped from 4+$ to where we are today. Now it looks like the committee was wrong and the results are proving the drug do work. Why is ARGS than still trading at 0.18 cent? ARGS was also ready to expend the company if they where thinking of doing that where would they get the money from? Something's brewing and I think we will found out soon.

Read more: Committee Suggests Argos Halt Cancer Study (ARGS) | Investopedia http://www.investopedia.com/news/committee-suggests-argos-halt-cancer-study-args/#ixzz4tIQGTy9B